ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last2,741 to 2,760 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
IC51 vs Placebo: serious adverse events10 of 1,993

6 of 657

-0.4 points

-1.5 to 0.2

2,650NCT00605085

Safety and Tolerability of the Japanese Encephalitis Vaccine IC51

CGAO-based Glucose Control vs Standard-Care Glucose Gontrol: All-cause In-hospital Mortality376 of 1,336

393 of 1,312

-1.8 points

-5.3 to 1.6

2,648NCT01002482

Computerized Glucose Control in Critically Ill Patients

CGAO-based Glucose Control vs Standard-Care Glucose Gontrol: All-cause 28-day Mortality326 of 1,336

328 of 1,312

-0.6 points

-3.9 to 2.7

2,648NCT01002482

Computerized Glucose Control in Critically Ill Patients

CGAO-based Glucose Control vs Standard-Care Glucose Gontrol: All-cause 90-day Mortality431 of 1,336

447 of 1,312

-1.8 points

-5.4 to 1.8

2,648NCT01002482

Computerized Glucose Control in Critically Ill Patients

CGAO-based Glucose Control vs Standard-Care Glucose Gontrol: All-cause Intensive Care Unit Mortality302 of 1,336

310 of 1,312

-1.0 points

-4.2 to 2.2

2,648NCT01002482

Computerized Glucose Control in Critically Ill Patients

CGAO-based Glucose Control vs Standard-Care Glucose Gontrol: serious adverse events20 of 1,336

6 of 1,312

1.0 points

0.3 to 1.9

2,648NCT01002482

Computerized Glucose Control in Critically Ill Patients

Intent-to-Treat (ITT) Responder Atrasentan vs Intent-to-Treat (ITT) Responder Placebo: Time to the First Occurrence of a Component of the Composite Renal Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized)79 of 1,325

105 of 1,323

-2.0 points

-3.9 to -0.0

2,648NCT01858532

Study Of Diabetic Nephropathy With Atrasentan

Intent-to-Treat (ITT) Responder Atrasentan vs Intent-to-Treat (ITT) Responder Placebo: Time to a 50% Estimated Glomerular Filtration Rate Reduction in the Intent-to-Treat (ITT) Responder Set (as Randomized)78 of 1,325

88 of 1,323

-0.8 points

-2.6 to 1.1

2,648NCT01858532

Study Of Diabetic Nephropathy With Atrasentan

Intent-to-Treat (ITT) Responder Atrasentan vs Intent-to-Treat (ITT) Responder Placebo: Time to Cardio-renal Composite Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized)147 of 1,325

172 of 1,323

-1.9 points

-4.4 to 0.6

2,648NCT01858532

Study Of Diabetic Nephropathy With Atrasentan

Intent-to-Treat (ITT) Responder Atrasentan vs Intent-to-Treat (ITT) Responder Placebo: Time to the Cardiovascular Composite Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized)72 of 1,325

81 of 1,323

-0.7 points

-2.5 to 1.1

2,648NCT01858532

Study Of Diabetic Nephropathy With Atrasentan

Intensive Control of SBP vs Standard Control of SBP: Number of CKD Participants Who Experienced a 50% Decline From Baseline eGFR10 of 1,330

12 of 1,316

-0.2 points

-0.9 to 0.6

2,646NCT01206062

Systolic Blood Pressure Intervention Trial

Celecoxib vs Placebo: Number of Participants With Incidence of Second Primary Breast Cancers19 of 1,763

12 of 876

-0.3 points

-1.4 to 0.5

2,639NCT02429427

European Celecoxib Trial in Primary Breast Cancer

Celecoxib vs Placebo: deaths from any cause203 of 1,763

104 of 876

-0.4 points

-3.1 to 2.2

2,639NCT02429427

European Celecoxib Trial in Primary Breast Cancer

T+OFS vs E+OFS: serious adverse events484 of 1,321

496 of 1,317

-1.0 points

-4.7 to 2.7

2,638NCT00066703

Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Group 1: Ad26.Mos.HIV Vaccine vs Group 2: Placebo: deaths from any cause5 of 1,317

4 of 1,319

0.1 points

-0.4 to 0.6

2,636NCT03060629

A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa

Group 1: Ad26.Mos.HIV Vaccine vs Group 2: Placebo: serious adverse events49 of 1,317

37 of 1,319

0.9 points

-0.5 to 2.3

2,636NCT03060629

A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa

Group 1: Ad26.Mos.HIV Vaccine vs Group 2: Placebo: Number of Participants With HIV-1 Infection Diagnosed From Enrollment (Baseline) Through Month 24 Post Enrollment91 of 1,311

102 of 1,319

-0.8 points

-2.8 to 1.2

2,630NCT03060629

A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa

Group 1: Ad26.Mos.HIV Vaccine vs Group 2: Placebo: Number of Participants With HIV-1 Infection Diagnosed From Enrollment (Baseline) Through Month 36 (End of Study) Post Enrollment115 of 1,311

127 of 1,319

-0.9 points

-3.1 to 1.4

2,630NCT03060629

A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa

Dapivirine Vaginal Ring vs Placebo Ring: deaths from any cause4 of 1,313

3 of 1,316

0.1 points

-0.4 to 0.6

2,629NCT01617096

Phase 3 Safety and Effectiveness Trial of Dapivirine Vaginal Ring for Prevention of HIV-1 in Women

Dapivirine Vaginal Ring vs Placebo Ring: The Number of Participants That Experienced Grade 2, 3, 4 and Serious Adverse Events Over the Investigational Product Used Period (25 mg Dapivirine Administered in a Silicone Elastomer Vaginal Matrix Ring (DVR), Inserted Once Every 4 Weeks).1,237 of 1,313

1,231 of 1,316

0.7 points

-1.2 to 2.5

2,629NCT01617096

Phase 3 Safety and Effectiveness Trial of Dapivirine Vaginal Ring for Prevention of HIV-1 in Women

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=138"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=138

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00605085-sae",
        "title": "IC51 vs Placebo: serious adverse events",
        "summary": "10 of 1993 against 6 of 657; risk difference -0.4 points, 95% interval -1.5 to 0.2; NCT00605085, Safety and Tolerability of the Japanese Encephalitis Vaccine IC51",
        "record": "/library/comparisons/NCT00605085-sae",
        "nct_id": "NCT00605085",
        "kind": "serious-adverse-events",
        "participants": 2650,
        "risk_difference": {
          "value": -0.004114858626196253,
          "lower": -0.015005531671320394,
          "upper": 0.002365866764603793
        },
        "group_1": "10 of 1,993",
        "group_2": "6 of 657",
        "difference": "-0.4 points",
        "interval": "-1.5 to 0.2",
        "trial_title": "Safety and Tolerability of the Japanese Encephalitis Vaccine IC51"
      },
      {
        "id": "NCT01002482-778f261c",
        "title": "CGAO-based Glucose Control vs Standard-Care Glucose Gontrol: All-cause In-hospital Mortality",
        "summary": "376 of 1336 against 393 of 1312; risk difference -1.8 points, 95% interval -5.3 to 1.6; NCT01002482, Computerized Glucose Control in Critically Ill Patients",
        "record": "/library/comparisons/NCT01002482-778f261c",
        "nct_id": "NCT01002482",
        "kind": "outcome",
        "participants": 2648,
        "risk_difference": {
          "value": -0.018105557178326293,
          "lower": -0.05263973940891209,
          "upper": 0.016463727196489836
        },
        "group_1": "376 of 1,336",
        "group_2": "393 of 1,312",
        "difference": "-1.8 points",
        "interval": "-5.3 to 1.6",
        "trial_title": "Computerized Glucose Control in Critically Ill Patients"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=139",
  "request_id": "L3ezhc_sFGE9g8JK"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?